In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic analog Rusfertide | Natural peptide Exenatide (exendin-4) | |
|---|---|---|---|
| Identity | |||
| Kind | Synthetic analog | Natural peptide | |
| Area | Weight and metabolic | Weight and metabolic | |
| Evidence | |||
| Amount of evidence | 78 | 3,292 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 21 (21 in people) | 449 (415 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 10 · 4 active | 322 · 11 active54 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
The FDA label for Mimrylo says: “Erythrocytosis in adults with polycythemia vera”
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Rusfertide | Exenatide (exendin-4) |
|---|---|---|
| Adverse eventsWhole body | 1616 | 27225121 |
| PharmacokineticsPharmacology |
PepBank is a research reference. Talk to a doctor before you use any peptide.
The FDA label for Byetta says: “Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus” No central EU authorisation (EMA).
2323
12978492 |
| Heart functionCardiovascular | 66 | 14882606 |
|---|
| Liver fat and liver functionLiver | 11 | 4826211 |
|---|
| Blood biochemical markersWhole body | 1313 | 55 |
|---|
| MortalityWhole body | 11 | 17116 |
|---|
| Patient-reported outcomesWhole body | 11 | 1111 |
|---|
| Overall treatment effectWhole body | 22 | 44 |
|---|
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 10 trials, ranked by phase, then posted results and enrollment: 2 ongoing · 1 completed · 2 with posted results · source ClinicalTrials.gov (opens in a new tab)
Protagonist Therapeutics, Inc.293 participants11 Apr 2022 to est. 31 Aug 2028
Polycythemia Vera
Protagonist Therapeutics, Inc.46 participants22 Jan 2024 to est. 1 Apr 2027
Polycythemia Vera
Protagonist Therapeutics, Inc.16 participants19 Mar 2020 to 15 Feb 2022
Hereditary Hemochromatosis
Top 3 of 322 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
AstraZeneca14,752 participants18 Jun 2010 to 24 Apr 2017
Type 2 Diabetes Mellitus
AstraZeneca1,036 participantsSept 2009 to Aug 2012
Type 2 Diabetes Mellitus
AstraZeneca1,029 participantsSept 2006 to Mar 2011
Type 2 Diabetes Mellitus
54 more mention it but do not test it. They only measure it or name it in their text.
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
| Outcome | Rusfertide | Exenatide (exendin-4) |
|---|---|---|
| Heart functionCardiovascularCompared as: value in the arm that got the peptide, in ms | 0.04 ms Predicted ΔΔQTcF at geometric mean Cmax Dose studied: 90 mgn = 602025 | < 10 ms Upper bound of 90% CI, placebo-corrected baseline-adjusted QTcP n not reported2013 |
0.04 ms
Predicted ΔΔQTcF at geometric mean Cmax
Dose studied: 90 mgn = 602025
< 10 ms
Upper bound of 90% CI, placebo-corrected baseline-adjusted QTcP
n not reported2013
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Rusfertide | Exenatide (exendin-4) |
|---|---|---|
| PharmacokineticsPharmacologyCompared as: difference from placebo, in % | No comparable result 23 randomized-trial results measure it in another way or another unit. | 11 to 24% Reduction in acetaminophen AUC(0-12 h) Dose studied: 10 mugn = 392005 |
| Blood biochemical markersWhole bodyCompared as: value in the arm that got the peptide, in ng/ml | No comparable result 6 randomized-trial results measure it in another way or another unit. | 46.54 ng/mL Circulating ZAG Dose studied: 10 μg twice daily12 weeksn not reported2019 |
|---|
| Patient-reported outcomesWhole bodyCompared as: value in the arm that got the peptide, in score | No randomized trial result 1 result from other study designs. | 1.66 score Change in overall treatment satisfaction (DTSQs) · exenatide, from baseline at week 26 Dose studied: 10 μg twice daily26 weeksn = 3792011 |
|---|
| Liver fat and liver functionLiverCompared as: value in the arm that got the peptide, in % | No randomized trial result 1 result from other study designs. | 93.3% Reversal rate 12 weeksn = 602014 |
|---|
| Adverse eventsWhole bodyCompared as: value in the arm that got the peptide, in % | No comparable result 11 randomized-trial results measure it in another way or another unit. | 14% Headache Placebo: 4% Dose studied: 10 µg twice daily30 weeksn not reported2011 |
|---|
No comparable result
23 randomized-trial results measure it in another way or another unit.
11 to 24%
Reduction in acetaminophen AUC(0-12 h)
Dose studied: 10 mugn = 392005
No comparable result
6 randomized-trial results measure it in another way or another unit.
46.54 ng/mL
Circulating ZAG
Dose studied: 10 μg twice daily12 weeksn not reported2019
No randomized trial result
1 result from other study designs.
1.66 score
Change in overall treatment satisfaction (DTSQs) · exenatide, from baseline at week 26
Dose studied: 10 μg twice daily26 weeksn = 3792011
No randomized trial result
1 result from other study designs.
93.3%
Reversal rate
12 weeksn = 602014
No comparable result
11 randomized-trial results measure it in another way or another unit.
14%
Headache
Placebo: 4%
Dose studied: 10 µg twice daily30 weeksn not reported2011